Acorda Therapeutics, Inc. (ACOR) Social Stream
Acorda Therapeutics Inc (ACOR) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering ACOR.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
Price Target Last Issued June 17, 2021
The Trend in the Analyst Price Target
ACOR's average price target has moved down $0 over the prior 65 days.
Over the past 170 days, ACOR's average upside potential has been 151.59%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
ACOR Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
ACOR's average broker recommendation rating improved by 0.5 over the prior 48 weeks.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- Acorda Therapeutics Inc's number of analysts covering the stock is higher than nearly none of all US stocks.
- In the context of all US stocks, Acorda Therapeutics Inc's variance in analysts' estimates is lower than almost 100% of them.
- In the context of stocks in the small market cap category, Acorda Therapeutics Inc's upside potential (average analyst target price relative to current price) is greater than 89.03% of them.
- To contextualize these metrics, consider that out of Healthcare stocks, Acorda Therapeutics Inc's average analyst price target is higher than 15.1% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Acorda Therapeutics Inc are ACHL, ABOS, and MTEX.
Make investment decisions regarding ACOR using the data that counts. Try POWR Ratings for free.